New Network Enhances Care for Bronchiectasis and NTM Lung Disease Patients
The patient care network will facilitate access to specialized care and support for individuals with bronchiectasis and NTM lung disease.
The patient care network will facilitate access to specialized care and support for individuals with bronchiectasis and NTM lung disease.
The FDA approved the first cell-based gene therapies for the treatment of sickle cell disease in patients 12 years and older. One therapy, Casgevy, is the first FDA-approved treatment to utilize the genome editing technology CRISPR/Cas9
Research reinforced the efficacy and safety of Acthar Gel, an FDA-approved therapy for autoimmune and inflammatory diseases like sarcoidosis.
The US Food and Drug Administration accepted a supplemental New Drug Application for an expanded indication of ofev (nintedanib) to treat children and adolescents between 6 to 17 years old with fibrosing interstitial lung disease.
Read MoreMerck’s investigational drug for chronic cough is one step closer to coming to market after receiving a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use.
Read MoreMyasthenia gravis is a chronic autoimmune, neuromuscular disease that causes weakness in skeletal muscle, including muscles needed for respiration.
Read MoreA treatment for the rare cancer-like lung disease found in women of childbearing age may have been discovered by University of Cincinnati researchers.
Read MoreIn this on-demand webinar from RT Magazine, a panel of respiratory care experts discussed effective and successful strategies for treating bronchiectasis.
Read MoreThe tool, which has been granted FDA Breakthrough Device Designation, is being developed to serve as adjunct in assessment of ILD, potentially avoiding expensive, invasive surgical testing.
Read MoreThe VA is studying the chronic symptoms of Gulf War Illness, a disease that includes respiratory dysfunction and affects about one-third of US veterans who served in the Persian Gulf.
Read MoreBronchiectasis is linked to several underlying causative agents and involves permanent airway damage, dilated bronchi, retained secretions, chronic infection, and persistent inflammation. But respiratory therapists have several airway clearance therapy options to treat the disease.
Read MoreChronic rhinitis patients treated with the Neuromark System demonstrated significant improvement in rhinorrhea and nasal congestion symptoms at 3 months, according to new data.
Read MoreThe expansion of the clinical trial follows the clearance of an Investigational New Drug application by the US Food and Drug Administration, announced earlier this year.
Read MoreNeurent Medical’s Neuromark Rhinitis Neurolysis Therapy (RNT) is now commercially available in limited US markets, the company reports.
Read MoreEndocannabinoids—cannabinoids produced within the body—are part of a process that help dilate the airways, and deficiencies could play a role in obstructive lung diseases like asthma.
Read More